← Back to screener

Xenon Pharmaceuticals Inc. XENE

Rank #2197 · Nasdaq · $3.6B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
29.6
P/E
-19.8
P/B
5.01
ROE
-25.3%
Op. Margin
–%
Debt Ratio
6%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -19.8x, P/B 5.01x. Ranks in the top 72% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -25.3%. Ranks in the top 83% of the universe.

Safety ★★★★★
Excellent

Debt ratio 6%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 100.0% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.0B$-0.0B$-0.0B$-0.1B-22.0-35
2015$0.0B$0.0B$0.0B$-0.1B35.5-16
2016$0.0B$0.0B$0.0B$-0.1B39.1-4
2017$0.0B$-0.0B$-0.0B$0.1B-60.15
2018$0.0B$-0.0B$-0.0B$0.1B-10474.316
2019$0.0B$-0.0B$-0.0B$0.0B-557.053
2020$0.0B$-0.0B$-0.0B$0.1B-627.054
2021$0.0B$-0.0B$-0.0B$0.1B-97.319
2022$0.0B$-0.0B$-0.0B$0.1B-97.324
2023$0.0B$-0.1B$-0.1B$0.2B-428.419
2024$0.0B$-0.1B$-0.1B$0.6B-1368.97
2025$0.0B$-0.2B$-0.2B$0.7B–6

← See the full screener